Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma Reply

DA Fennell, P Taylor, D Gilligan, T Nakano, A Scherpereel, N Pavlakis, JP van Meerbeeck, Joachim Aerts, AK Nowak, H Kindler, P Baas

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
Original languageUndefined/Unknown
Pages (from-to)2294-+
JournalJournal of Clinical Oncology
Volume37
Issue number25
DOIs
Publication statusPublished - 2019

Research programs

  • EMC MM-04-42-02

Cite this